In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 361 to 370 of 387

TitleTypeExpected publication date
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidanceTBC
Type 2 diabetes in adults: management (medicines update)NICE guideline
Upadacitinib for treating giant cell arteritis [ID6299]Technology appraisal guidance
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]Technology appraisal guidance
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Technology appraisal guidanceTBC
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adultsInterventional procedures guidance
Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) in adults in refractory cardiac arrestInterventional procedures guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All